Middle East and Africa Dengue Treatment Market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 OBJECTIVES OF THE STUDY
• 1.2 MARKET DEFINITION
• 1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET
• 1.4 CURRENCY AND PRICING
• 1.5 LIMITATIONS
• 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

• 2.1 MARKETS COVERED
• 2.2 GEOGRAPHICAL SCOPE
• 2.3 YEARS CONSIDERED FOR THE STUDY
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
• 2.6 MULTIVARIATE MODELLING
• 2.7 MARKET APPLICATION COVERAGE GRID
• 2.8 PRODUCT LIFELINE CURVE
• 2.9 DBMR MARKET POSITION GRID
• 2.10 VENDOR SHARE ANALYSIS
• 2.11 SECONDARY SOURCES
• 2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PESTEL ANALYSIS
• 4.2 PORTER'S FIVE FORCES

5 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: REGULATIONS

• 5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
• 5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
• 5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
• 5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
• 5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK

6 MARKET OVERVIEW

• 6.1 DRIVERS
  • 6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT
  • 6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES
  • 6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
  • 6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
• 6.2 RESTRAINTS
  • 6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES
  • 6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE
  • 6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE
• 6.3 OPPORTUNITIES
  • 6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET
  • 6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT
  • 6.3.3 RISING R&D INVESTMENT AND ACTIVITIES
• 6.4 CHALLENGES
  • 6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS
  • 6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS

7 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS

• 7.1 OVERVIEW
• 7.2 DENV-2
• 7.3 DENV-3
• 7.4 DENV-1
• 7.5 DENV-4
• 7.6 OTHERS

8 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE

• 8.1 OVERVIEW
• 8.2 VACCINES
  • 8.2.1 DENGVAXIA (CYD-TDV)
  • 8.2.2 QDENGA
• 8.3 ACETAMINOPHEN
  • 8.3.1 PARENTERAL
  • 8.3.2 ORAL
  • 8.3.3 OTHER

9 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY

• 9.1 OVERVIEW
• 9.2 MILD TO MODERATE DENGUE
• 9.3 SEVERE DENGUE

10 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

• 10.1 OVERVIEW
• 10.2 PARENTERAL
  • 10.2.1 SUB-CUTANEOUS
  • 10.2.2 INTRAVENOUS
• 10.3 ORAL
  • 10.3.1 TABLET
  • 10.3.2 CAPSULES
  • 10.3.3 OTHERS

11 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE

• 11.1 OVERVIEW
• 11.2 PRESCRIPTION
• 11.3 OVER-THE-COUNTER (OTC)

12 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GENDER

• 12.1 OVERVIEW
• 12.2 MALE
• 12.3 FEMALE

13 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY AGE

• 13.1 OVERVIEW
• 13.2 ADULT
• 13.3 PEDIATRIC
• 13.4 GERIATRIC

14 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER

• 14.1 OVERVIEW
• 14.2 HOSPITAL
• 14.3 SPECIALTY CLINICS
• 14.4 HOME HEALTHCARE
• 14.5 OTHERS

15 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 15.1 OVERVIEW
• 15.2 RETAIL PHARMACIES
• 15.3 HOSPITAL PHARMACIES
• 15.4 ONLINE PHARMACIES

16 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY REGION

• 16.1 MIDDLE EAST AND AFRICA
  • 16.1.1 EGYPT
  • 16.1.2 SAUDI ARABIA
  • 16.1.3 SOUTH AFRICA
  • 16.1.4 U.A.E
  • 16.1.5 ISRAEL
  • 16.1.6 REST OF MIDDLE EAST AND AFRICA

17 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

• 19.1 SANOFI
  • 19.1.1 COMPANY SNAPSHOT
  • 19.1.2 REVENUE ANALYSIS
  • 19.1.3 COMPANY SHARE ANALYSIS
  • 19.1.4 PRODUCT PORTFOLIO
  • 19.1.5 RECENT DEVELOPMENTS
• 19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • 19.2.1 COMPANY SNAPSHOT
  • 19.2.2 REVENUE ANALYSIS
  • 19.2.3 COMPANY SHARE ANALYSIS
  • 19.2.4 PRODUCT PORTFOLIO
  • 19.2.5 RECENT DEVELOPMENTS
• 19.3 VIATRIS INC.
  • 19.3.1 COMPANY SNAPSHOT
  • 19.3.2 REVENUE ANALYSIS
  • 19.3.3 COMPANY SHARE ANALYSIS
  • 19.3.4 PRODUCT PORTFOLIO
  • 19.3.5 RECENT DEVELOPMENTS
• 19.4 JOHNSON & JOHNSON SERVICES, INC.
  • 19.4.1 COMPANY SNAPSHOT
  • 19.4.2 REVENUE ANALYSIS
  • 19.4.3 COMPANY SHARE ANALYSIS
  • 19.4.4 PRODUCT PORTFOLIO
  • 19.4.5 RECENT DEVELOPMENT
• 19.5 GSK PLC.
  • 19.5.1 COMPANY SNAPSHOT
  • 19.5.2 REVENUE ANALYSIS
  • 19.5.3 COMPANY SHARE ANALYSIS
  • 19.5.4 PRODUCT PORTFOLIO
  • 19.5.5 RECENT DEVELOPMENTS
• 19.6 AUROBINDO PHARMA
  • 19.6.1 COMPANY SNAPSHOT
  • 19.6.2 REVENUE ANALYSIS
  • 19.6.3 PRODUCT PORTFOLIO
• 19.7 BAXTER
  • 19.7.1 COMPANY SNAPSHOT
  • 19.7.2 REVENUE ANALYSIS
  • 19.7.3 PRODUCT PORTFOLIO
• 19.8 FRESENIUS KABI USA
  • 19.8.1 COMPANY SNAPSHOT
  • 19.8.2 PRODUCT PORTFOLIO
  • 19.8.3 RECENT DEVELOPMENTS
• 19.9 HIKMA PHARMACEUTICALS
  • 19.9.1 COMPANY SNAPSHOT
  • 19.9.2 REVENUE ANALYSIS
  • 19.9.3 PRODUCT PORTFOLIO
  • 19.9.4 RECENT DEVELOPMENT
• 19.10 PERRIGO COMPANY PLC
  • 19.10.1 COMPANY SNAPSHOT
  • 19.10.2 REVENUE ANALYSIS
  • 19.10.3 PRODUCT PORTFOLIO
  • 19.10.4 RECENT DEVELOPMENT
• 19.11 PFIZER INC.
  • 19.11.1 COMPANY SNAPSHOT
  • 19.11.2 REVENUE ANALYSIS
  • 19.11.3 PRODUCT PORTFOLIO
  • 19.11.4 RECENT DEVELOPMENTS
• 19.12 SUN PHARMACEUTICAL INDUSTRIES LTD
  • 19.12.1 COMPANY SNAPSHOT
  • 19.12.2 REVENUE ANALYSIS
  • 19.12.3 PRODUCT PORTFOLIO
  • 19.12.4 RECENT DEVELOPMENT
• 19.13 TEVA PHARMACEUTICALS USA, INC.
  • 19.13.1 COMPANY SNAPSHOT
  • 19.13.2 REVENUE ANALYSIS
  • 19.13.3 PRODUCT PORTFOLIO
  • 19.13.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

LIST OF TABLES

• TABLE 1 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
• TABLE 2 IMPACT OF DELAY IN APPROVAL PROCESS
• TABLE 3 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 4 MIDDLE EAST AND AFRICA DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 5 MIDDLE EAST AND AFRICA DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 6 MIDDLE EAST AND AFRICA DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 7 MIDDLE EAST AND AFRICA DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 8 MIDDLE EAST AND AFRICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 9 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 10 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 11 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 12 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 13 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 14 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 15 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 16 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 17 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 18 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 19 MIDDLE EAST AND AFRICA MILD TO MODERATE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 20 MIDDLE EAST AND AFRICA SEVERE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 21 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 22 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 23 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 24 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 25 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 26 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 27 MIDDLE EAST AND AFRICA PRESCRIPTION IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 28 MIDDLE EAST AND AFRICA OVER-THE-COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 29 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 30 MIDDLE EAST AND AFRICA MALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 31 MIDDLE EAST AND AFRICA FEMALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 32 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 33 MIDDLE EAST AND AFRICA ADULT IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 34 MIDDLE EAST AND AFRICA PEDIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 35 MIDDLE EAST AND AFRICA GERIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 36 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 37 MIDDLE EAST AND AFRICA HOSPITAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 38 MIDDLE EAST AND AFRICA SPECIALITY CLINICS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 39 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 41 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 42 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 43 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 44 MIDDLE EAST AND AFRICA ONLINE PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 45 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
• TABLE 46 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 47 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 48 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 49 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 50 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 51 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 52 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 53 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 54 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 55 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 56 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 57 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 58 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 59 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 60 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 61 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 62 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 63 EGYPT DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 64 EGYPT DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 65 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 66 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 67 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 68 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 69 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 70 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 71 EGYPT DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 72 EGYPT DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 73 EGYPT PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 74 EGYPT ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 75 EGYPT DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 76 EGYPT DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 77 EGYPT DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 78 EGYPT DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 79 EGYPT DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 80 SAUDI ARABIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 81 SAUDI ARABIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 82 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 83 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 84 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 85 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 86 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 87 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 88 SAUDI ARABIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 89 SAUDI ARABIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 90 SAUDI ARABIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 91 SAUDI ARABIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 92 SAUDI ARABIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 93 SAUDI ARABIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 94 SAUDI ARABIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 95 SAUDI ARABIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 96 SAUDI ARABIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 97 SOUTH AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 98 SOUTH AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 99 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 100 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 101 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 102 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 103 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 104 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 105 SOUTH AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 106 SOUTH AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 107 SOUTH AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 108 SOUTH AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 109 SOUTH AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 110 SOUTH AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 111 SOUTH AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 112 SOUTH AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 113 SOUTH AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 114 U.A.E DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 115 U.A.E DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 116 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 117 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 118 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 119 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 120 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 121 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 122 U.A.E DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 123 U.A.E DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 124 U.A.E PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 125 U.A.E ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 126 U.A.E DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 127 U.A.E DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 128 U.A.E DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 129 U.A.E DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 130 U.A.E DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 131 ISRAEL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 132 ISRAEL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 133 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 134 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 135 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 136 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 137 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 138 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 139 ISRAEL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 140 ISRAEL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 141 ISRAEL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 142 ISRAEL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 143 ISRAEL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 144 ISRAEL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 145 ISRAEL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 146 ISRAEL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 147 ISRAEL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 148 REST OF MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

LIST OF FIGURES

• FIGURE 1 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: SEGMENTATION
• FIGURE 2 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: DATA TRIANGULATION
• FIGURE 3 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: DROC ANALYSIS
• FIGURE 4 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
• FIGURE 5 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
• FIGURE 6 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
• FIGURE 7 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
• FIGURE 8 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
• FIGURE 9 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
• FIGURE 10 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: SEGMENTATION
• FIGURE 11 GROWING PHARMACEUTICAL INDUSTRY IS DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET FROM 2024 TO 2031
• FIGURE 12 ON THE BASIS OF STRAINS, THE DENV-2 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET IN 2024 AND 2031
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET
• FIGURE 14 FINANCIAL BUDGET FOR VECTOR-BORNE -DISEASES INCLUDING DENGUE IN INDIA
• FIGURE 15 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, 2023
• FIGURE 16 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, 2024-2031 (USD MILLION)
• FIGURE 17 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2024-2031)
• FIGURE 18 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
• FIGURE 19 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, 2023
• FIGURE 20 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)
• FIGURE 21 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, CAGR (2024-2031)
• FIGURE 22 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
• FIGURE 23 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY, 2023
• FIGURE 24 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY, 2024-2031 (USD MILLION)
• FIGURE 25 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2024-2031)
• FIGURE 26 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
• FIGURE 27 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023
• FIGURE 28 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
• FIGURE 29 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
• FIGURE 30 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
• FIGURE 31 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2023
• FIGURE 32 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
• FIGURE 33 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2024-2031)
• FIGURE 34 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
• FIGURE 35 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY GENDER, 2023
• FIGURE 36 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)
• FIGURE 37 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY GENDER, CAGR (2024-2031)
• FIGURE 38 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY GENDER, LIFELINE CURVE
• FIGURE 39 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY AGE, 2023
• FIGURE 40 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY AGE, 2024-2031 (USD MILLION)
• FIGURE 41 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY AGE, CAGR (2024-2031)
• FIGURE 42 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY AGE, LIFELINE CURVE
• FIGURE 43 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, 2023
• FIGURE 44 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)
• FIGURE 45 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, CAGR (2024-2031)
• FIGURE 46 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
• FIGURE 47 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023
• FIGURE 48 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
• FIGURE 49 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
• FIGURE 50 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
• FIGURE 51 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: SNAPSHOT (2023)
• FIGURE 52 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)